AB0521 Safety, pharmacokinetics, and pharmacodynamics of single doses of a bispecific icosl and baff inhibitor, amg 570, in healthy subjects

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 1418
• Main Authors: Cheng, L.E., Kankam, M., Siebers, N., Stoltz, R., Abuqayyas, L., Ertik, B., Sullivan, B.A., Zhou, L., Mitragotri, D., Parnes, J.R.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2018
• Subjects: Autoimmune diseases; BLyS protein; Cell surface; Costimulator; Erythema; Immunoglobulin G; Immunoglobulin M; Immunological memory; Lymphocytes B; Lymphocytes T; Market shares; Memory cells; Pharmacodynamics; Pharmacokinetics; Respiratory tract diseases; Stockholders; Systemic lupus erythematosus

BackgroundAutoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulation in both T cell and B cell responses. Targeting the activity of both cell types simultaneously holds promise as a treatment for autoimmune disease. AMG 570 is a bispecific molecule targeting...